Norway’s Ultimovacs AS has carried out a successful NOK 45 million share issue with DNB Markets and Arctic Securities as financial advisors. The issue was fully subscribed by new shareholders. The two biggest new shareholders are Canica AS and Sundt AS.
Ultimovacs is a biotechnology company that develops a therapeutic universal cancer vaccine. The treatment is not linked to a specific type of cancer, but has the potential to trigger a general immunologic reaction against cancer cells, regardless of the type of cancer. Stimulating the immune system to attack cancer cells is a new form of cancer treatment that is developing rapidly internationally.